15 July 2009
Asher Mullard
asher.mullard@informa.com
Bayer and Johnson & Johnson plan to submit a reply to the US FDA's complete response letter on Xarelto (rivaroxaban), a potential blockbuster anticoagulant, in the fourth quarter of this year.
Xarelto was developed by Bayer and will be marketed in the US, if approved, by Johnson & Johnson's...
Please Login to read the full article.
RELATED CONTENT
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
